Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Liabilities and Shareholders Equity (2022 - 2025)

Entrada Therapeutics has reported Liabilities and Shareholders Equity over the past 4 years, most recently at $377.4 million for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $377.4 million for Q4 2025, down 28.3% from a year ago — trailing twelve months through Dec 2025 was $1.7 billion (down 20.62% YoY), and the annual figure for FY2025 was $377.4 million, down 28.3%.
  • Liabilities and Shareholders Equity for Q4 2025 was $377.4 million at Entrada Therapeutics, down from $412.9 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for TRDA hit a ceiling of $582.0 million in Q2 2024 and a floor of $252.1 million in Q4 2022.
  • Median Liabilities and Shareholders Equity over the past 4 years was $472.4 million (2023), compared with a mean of $435.1 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: skyrocketed 86.15% in 2023 and later decreased 28.3% in 2025.
  • Entrada Therapeutics' Liabilities and Shareholders Equity stood at $252.1 million in 2022, then soared by 86.15% to $469.2 million in 2023, then rose by 12.18% to $526.3 million in 2024, then dropped by 28.3% to $377.4 million in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $377.4 million (Q4 2025), $412.9 million (Q3 2025), and $448.8 million (Q2 2025) per Business Quant data.